Idiopathic Pulmonary Fibrosis Pipeline Analysis, 2016 - Clinical Trials & Results, Collaboration and Other Developments

The study analyzed that the IPF pipeline comprised of 97 therapeutic candidates, of which 15 are in Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. Various drugs are being developed as novel and promising therapeutics for the treatment of IPF.

Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market

As per the findings of research, it was found that around 9% IPF candidate target chemokine, 7% target integrin and 6% of the product candidates target G-protein couple receptor. Other targets comprising 78% of candidates of IPF pipeline include, but not limited to, autotaxin, connective tissue growth factor-associated, fibroblast growth factor, lysyl-oxidase like protein 2 and tissue growth factor beta. Around 55% pipeline therapeutic candidates of IPF are being developed to be administered by oral route, 20% by inhalation route, 12% by intravenous route and 8% by subcutaneous route.

Browse Report Sample at: https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market/report-sample

U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted ODD to more than 10 drugs. As per the FDA, its Office of Orphan Products Development (OOPD) mission is to advance the evaluation and development of products (drugs, biologics, devices, or medical foods) that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions. Tipelukast, also known as MN-001, is under Phase II stage of development by MediciNova, Inc. for the treatment of IPF. The drug was granted ODD for the treatment of IPF, which will provide MediciNova with seven years of marketing exclusivity if it is approved for IPF. Some of the key players developing drugs candidates for the treatment of IPF are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Global Blood Therapeutics, Inc., Asahi Kasei Corporation, Beijing Tide Pharmaceutical Co., Limited, FibroGen, Inc., Chong Kun Dang Pharmaceutical Corp., Galapagos NV, Kadmon Holdings, Inc., MediciNova, Inc., and Promedior, Inc.